Stock TVTX TRAVERE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
6.16 USD -2.84% Intraday chart for Travere Therapeutics, Inc. +1.65% -31.48%
May. 15 Transcript : Travere Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM
May. 07 Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Travere Therapeutics : Corporate Overview – May 2024
PU
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Travere Therapeutics : Equity Incentive Plan - Form 8-K
PU
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
GL
Travere Therapeutics to Present at Upcoming Investor Conferences
GL
Travere: Q1 Earnings Snapshot
AQ
Travere Therapeutics Reports First Quarter 2024 Financial Results
GL
Travere Therapeutics to Report First Quarter 2024 Financial Results
GL
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI for the treatment of IgA Nephropathy
AQ
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
GL
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
GL
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
GL
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
GL
Travere Therapeutics to Present at Upcoming Investor Conferences
GL
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
AQ
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
GL
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TVTX Stock
  4. News Travere Therapeutics, Inc.
  5. Press Releases